Thermo Fisher Scientific Inc.
TMO
$424.40
-$2.26-0.53%
NYSE
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 42.88B | 42.37B | 42.35B | 42.49B | 42.86B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.88B | 42.37B | 42.35B | 42.49B | 42.86B |
| Cost of Revenue | 25.13B | 25.05B | 25.03B | 25.26B | 25.66B |
| Gross Profit | 17.75B | 17.32B | 17.31B | 17.23B | 17.20B |
| SG&A Expenses | 8.60B | 8.51B | 8.47B | 8.43B | 8.38B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 30.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Total Operating Expenses | 35.15B | 34.91B | 34.82B | 35.02B | 35.38B |
| Operating Income | 7.73B | 7.46B | 7.53B | 7.48B | 7.48B |
| Income Before Tax | 7.00B | 6.76B | 6.78B | 6.51B | 6.24B |
| Income Tax Expenses | 658.00M | 641.00M | 595.00M | 519.00M | 284.00M |
| Earnings from Continuing Operations | 6.34K | 6.12K | 6.19K | 6.00K | 5.96K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.00M | 14.00M | 34.00M | 39.00M | 40.00M |
| Net Income | 6.34B | 6.14B | 6.22B | 6.03B | 6.00B |
| EBIT | 7.73B | 7.46B | 7.53B | 7.48B | 7.48B |
| EBITDA | 10.84B | 10.66B | 10.85B | 10.86B | 10.88B |
| EPS Basic | 16.59 | 16.01 | 16.18 | 15.66 | 15.52 |
| Normalized Basic EPS | 12.05 | 11.54 | 11.62 | 11.49 | 11.26 |
| EPS Diluted | 16.53 | 15.95 | 16.12 | 15.59 | 15.45 |
| Normalized Diluted EPS | 12.01 | 11.49 | 11.58 | 11.44 | 11.21 |
| Average Basic Shares Outstanding | 1.53B | 1.53B | 1.54B | 1.54B | 1.55B |
| Average Diluted Shares Outstanding | 1.53B | 1.54B | 1.54B | 1.55B | 1.55B |
| Dividend Per Share | 1.56 | 1.52 | 1.48 | 1.44 | 1.40 |
| Payout Ratio | 9.20% | 9.29% | 8.92% | 8.97% | 8.72% |